Krystal Biotech, Inc. Stockholders Equity

Quick Answer

Krystal Biotech, Inc. reported Stockholders Equity of $1.22 billion for fiscal year 2025.

Krystal Biotech, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $1.22B +28.9%
2024 $946.38M +21.5%
2023 $778.64M +49.1%
2022 $522.23M -12.0%
2021 $593.58M +103.2%
2020 $292.08M +43.9%
2019 $202.91M +79.2%
2018 $113.23M +128.9%
2017 $49.47M +17019.0%
2016 $289.0K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $1.14B +28.5% +9.3%
June 30, 2025 $1.04B +24.1% +5.7%
March 31, 2025 $984.67M +23.2% +4.0%
December 31, 2024 $946.38M +21.5% +6.8%
September 30, 2024 $885.85M +17.2% +5.6%
June 30, 2024 $838.89M +28.4% +5.0%
March 31, 2024 $799.24M +63.3% +2.6%
December 31, 2023 $778.64M +49.1% +3.0%
  • Krystal Biotech, Inc. showed an increase of +28.9% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, Krystal Biotech, Inc.’s stockholders equity has grown by 421893.1% (from $289.0 thousand to $1.22 billion).
  • The most recent figure is from Krystal Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment